NCT04643418View on ClinicalTrials.gov

Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Solid Tumor, Unspecified, Adult
Interventions
DRUG

MPB-1734

Administered once daily in a 21-day cycle

Trial Locations (1)

112

RECRUITING

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
lead

MegaPro Biomedical Co. Ltd.

INDUSTRY